← Back to patent-cliff list
CAS 461-58-5
Codes: AZAC-009
Application context (from source-drug indications)
幼年型粒单核细胞白血病AzacitidineAcute myeloid leukaemiaAzacitidineMyelodysplastic syndromeAzacitidineChronic myeloid leukaemiaAzacitidineChronic myelomonocytic leukaemiaAzacitidine脑性瘫痪Azacitidine
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Azacitidine | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
4-amino-1,3,5-triazin-2(1H)-one→N-(trimethylsilyl)-4-((trimethylsilyl)oxy)-1,3,5-triazin-2-amine→(2S,3R,4R,5R)-5-(acetoxymethyl)tetrahydrofuran-2,3,4-triyl triacetate→AZAC-009→N-Methylformamide-001→1-(diaminomethylene)urea→(2R,3R,4R,5R)-2-(acetoxymethyl)-5-(4-amino-2-oxo-1,3,5-triazin-1(2H)-yl)tetrahydrofuran-3,4-diyl diacetate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.